Laurent Fischer, M.D.

Senior Advisor

Laurent is a Senior Advisor on the Frazier Life Sciences team and has over 20 years of drug development and commercialization experience in the biopharmaceutical industry.

Laurent joined Frazier Healthcare Partners' Life Sciences team as a Senior Advisor in March 2017. He currently serves as the President and Chief Executive Officer of Adverum Biotechnologies. He was previously Chief Executive Officer of Tobira Therapeutics, which was acquired by Allergan for up to $1.7 billion in 2016. He also serves on the board of directors of Mirum Pharmaceuticals (NASDAQ: MIRM), a Frazier portfolio company developing a novel approach for treating cholestatic liver diseases. The U.S. FDA has approved Mirum’s LIVMARLI™ (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older.

Prior to Tobira, Laurent was chairman and CEO of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy for Liver Cancer acquired for $150 million by Sillajen. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics. Laurent has also held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. He launched Sustiva®, the first once-daily anti-HIV and 10th top prescribed specialty drug in 2015, and was involved in the launch of the first protease inhibitor in the United States.

In addition to his role at Frazier, Laurent currently serves as Chairman of the board of CTI BioPharma, which is developing pacritinib for myelofibrosis. He also serves on the board of Lycia Therapeutics, which is developing potentially first-in-class therapeutics that degrade extracellular proteins to address difficult-to-treat diseases.

Laurent received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

South San Francisco

University of Geneva (M.D.)

Year Joined